The Administrative Core of the Mayo Alzheimer's Disease Research Center will be responsible for the overall management of the Center. It will provide fiscal management, scientific direction, accountability, and communication with the National Alzheimer Coordinating Center and with other Alzheimer's Disease Centers. The ADRC will continue to pursue the scientific themes of the previous grant cycle, focusing on early detection of AD, particularly in the mild cognitive impairment (MCI) stage, and also focusing on non-AD dementias. The center will strive to expand AD research within the entire institution and will promote AD and non-AD dementia research nationally and internationally. The Core will oversee the pilot project program. The Core will have an Internal Steering Committee headed by the Center Director, and this Committee will oversee the scientific, personnel and fiscal issues of the Center. The Committee will also make the final judgment with regard to the awarding of pilot projects. The Core will continue with its ExternalAdvisory Committee, and this group will meet on an annual basis, alternating between Rochester, MN, and Jacksonville, FL. The Administrative Core will oversee the interactions among the cores and projects and will also integrate activities between Rochester, MN, and Jacksonville, FL. The Center will continue to provide relevant data to the National Alzheimer's Coordinating Center and will be compliant with the Uniform Data Set requirements. The Center Director and the staff will be responsible for compliance with the training requirements for key personnel as outlined by the Mayo Foundation, and all activities will be HIPAA compliant. The Director will communicate with the National Institute on Aging and provide annual progress reports.

Public Health Relevance

(Seeinstructions): The Administrative Core of the ADRC oversees the overall function of the Center. The Core coordinates the activities of the two sites and integrates the activities of the cores and the projects to accomplish the scientific goals of the Center.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG016574-15
Application #
8460026
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
15
Fiscal Year
2013
Total Cost
$128,191
Indirect Cost
$43,353
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Wilmoth, Kristin; LoBue, Christian; Clem, Matthew A et al. (2018) Consistency of traumatic brain injury reporting in older adults with and without cognitive impairment. Clin Neuropsychol 32:524-529
Jones, David T; Knopman, David S; Graff-Radford, Jonathan et al. (2018) In vivo 18F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology 90:e947-e954
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Ting, Simon Kang Seng; Foo, Heidi; Chia, Pei Shi et al. (2018) Dyslexic Characteristics of Chinese-Speaking Semantic Variant of Primary Progressive Aphasia. J Neuropsychiatry Clin Neurosci 30:31-37
Wennberg, Alexandra M V; Lesnick, Timothy G; Schwarz, Christopher G et al. (2018) Longitudinal Association Between Brain Amyloid-Beta and Gait in the Mayo Clinic Study of Aging. J Gerontol A Biol Sci Med Sci 73:1244-1250
Wennberg, Alexandra M V; Hagen, Clinton E; Edwards, Kelly et al. (2018) Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population-based Mayo Clinic Study of Aging. Int J Geriatr Psychiatry 33:1114-1120
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Sahoo, Aradhana; Bejanin, Alexandre; Murray, Melissa E et al. (2018) TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnestic Alzheimer's Disease Dementia. J Alzheimers Dis 64:1227-1233

Showing the most recent 10 out of 1014 publications